Compugen Ltd (CGEN) Stock Price, Quote & News

Company Profile

Compugen Ltd., a clinical-stage therapeutic discovery and development company, engages in the research, development, and commercialization of therapeutics and product candidates in Israel, the United States, and Europe. The company's pipeline consists of COM701, an immuno-oncology pipeline program with an anti-PVRIG antibody; COM902, a therapeutic anti-TIGIT antibody, are in Phase 1 clinical trials and have been evaluated for the treatment of solid tumors as a monotherapy and in combination of P...

Industry: Biotechnology

Sector: Healthcare

Phone: 972 3 765 8585

Fax: 972 3 765 8555

Website: cgen.com

Address:

Azrieli Center, Building D 26 Harokmim Street, Holon, Israel

wenmoon_stonks Aug. 18 at 7:57 PM

$CGEN

0 · Reply

StayExcited Aug. 18 at 2:47 PM

$CGEN gotta break this 1.55! Next 1.63 Riz

0 · Reply

TwitteringTom Aug. 18 at 1:54 PM

$CGEN why this "moving" today

1 · Reply

Otus Aug. 13 at 2:43 PM

$CGEN bought a 10k block yesterday. Brings me to 240k shares. I will buy another 10k block on weakness. Long term extremely bullish!!

1 · Reply

vdonnelson Aug. 11 at 12:20 PM

$CGEN any risk of dilution to raise money in the near future, as in this month?

1 · Reply

wenmoon_stonks Aug. 7 at 2:02 PM

$CGEN shrim begin?

0 · Reply

wenmoon_stonks Aug. 6 at 2:31 PM

$CGEN

0 · Reply

Otus Aug. 6 at 2:09 PM

$CGEN wake up CGEN!! Anat exposure works better than sleeping pills

0 · Reply

TwitteringTom Aug. 5 at 6:15 PM

$CGEN what we getting tomorrow, bunch of nothing i assume

0 · Reply

Otus Jul. 28 at 9:19 PM

$CGEN nice press release this morning. You would think even though it didn’t release any type of results it should have enticed some buying. It seems my favorite small bio stocks are all run by people who have no clue about marketing or investor relations.

2 · Reply

Compugen: Potential Best-In-Class Anti-PVRIG COM701 Shifts To Targeting PSOC Patients

Aug 7, 2025, 6:30 AM EDT - 14 days ago

Compugen Ltd. (CGEN) Q2 2025 Earnings Call Transcript

Aug 6, 2025, 7:00 AM EDT - 15 days ago

Compugen Reports Second Quarter 2025 Results

Jul 28, 2025, 7:00 AM EDT - 24 days ago

Compugen to Present a Pooled Analysis of COM701 Phase 1 trials in Platinum Resistant Ovarian Cancer at ESMO 2025

Jul 23, 2025, 7:00 AM EDT - 4 weeks ago

Compugen to Release Second Quarter 2025 Results on Wednesday, August 6, 2025

Jul 21, 2025, 7:00 AM EDT - 4 weeks ago

Compugen Announces First Patient Dosed in COM701 Global Platform Trial in Platinum Sensitive Ovarian Cancer

Jun 12, 2025, 7:00 AM EDT - 2 months ago

Compugen to Present AI/ML Driven Predictive Computational Research at Upcoming International Scientific Conferences

May 19, 2025, 10:21 AM EDT - 3 months ago

Compugen Ltd. (CGEN) Q1 2025 Earnings Call Transcript

May 19, 2025, 7:00 AM EDT - 3 months ago

Compugen Reports First Quarter 2025 Results

May 13, 2025, 7:00 AM EDT - 3 months ago

Compugen Announces Leadership Transitions Effective September 2025

May 5, 2025, 7:00 AM EDT - 3 months ago

Compugen to Release First Quarter 2025 Results on Monday, May 19, 2025

Mar 26, 2025, 7:00 AM EDT - 5 months ago

Compugen to Participate in Multiple Virtual Investor Conferences in April 2025

Mar 4, 2025, 10:34 AM EST - 6 months ago

Compugen Ltd. (CGEN) Q4 2024 Earnings Call Transcript

Mar 4, 2025, 7:00 AM EST - 6 months ago

Compugen Reports Fourth Quarter and Full Year 2024 Results

Mar 3, 2025, 7:00 AM EST - 6 months ago

Compugen to Participate in a Fireside Chat at the 2025 Leerink Partners Global Healthcare Conference

Feb 26, 2025, 7:00 AM EST - 6 months ago

Compugen Enhances its AI/ML Predictive Computational Discovery Platform, Unigen™ with Ultima Genomics' Single Cell Genomics Sequencing Technology

Feb 18, 2025, 7:00 AM EST - 6 months ago

Compugen to Release Fourth Quarter and Full Year 2024 Financial Results on Tuesday, March 4, 2025

Feb 18, 2025, 6:11 AM EST - 6 months ago

Compugen: Immuno-Oncology Innovator Poised For A Comeback

Feb 4, 2025, 7:00 AM EST - 7 months ago

Compugen to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Jan 8, 2025, 7:00 AM EST - 8 months ago

Compugen Announces First Patient Dosed in Phase 1 Clinical Trial to Evaluate COM503 as Monotherapy and in Combination with Zimberelimab in Advanced Solid Tumors

Nov 27, 2024, 7:00 AM EST - 9 months ago

Compugen Expands its Intellectual Property Portfolio with New U.S. Patent Covering Triple Combination Use of COM902 (reduced Fc anti-TIGIT) with anti-PD-1 and anti-PVRIG Antibodies

Nov 12, 2024, 3:35 PM EST - 10 months ago

Compugen Ltd. (CGEN) Q3 2024 Earnings Call Transcript

Nov 12, 2024, 7:00 AM EST - 10 months ago

Compugen Reports Third Quarter 2024 Results

Nov 11, 2024, 7:00 AM EST - 10 months ago

Compugen to Participate in Stifel 2024 Healthcare Conference

Nov 5, 2024, 9:00 AM EST - 10 months ago

Compugen to Present Anti-Tumor Activity and Safety Data of COM701, COM902 and Pembrolizumab Combination in Patients with Platinum Resistant Ovarian Cancer at SITC 2024

Oct 29, 2024, 7:00 AM EDT - 10 months ago

Compugen to Release Third Quarter 2024 Financial Results on Tuesday, November 12, 2024

Oct 7, 2024, 7:00 AM EDT - 11 months ago

Compugen to Present New Clinical Data at SITC 2024

Sep 9, 2024, 7:00 AM EDT - 1 year ago

Compugen to Present at Single Cell Genomics 2024 Conference

Aug 29, 2024, 7:00 AM EDT - 1 year ago

Compugen to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Aug 10, 2024, 5:54 AM EDT - 1 year ago

Compugen Ltd. (CGEN) Q2 2024 Earnings Call Transcript

Aug 6, 2024, 7:00 AM EDT - 1 year ago

Compugen Reports Second Quarter 2024 Results

Jul 29, 2024, 7:00 AM EDT - 1 year ago

Compugen Announces FDA Clearance of IND for COM503 for the Treatment of Solid Tumors

Jul 23, 2024, 7:00 AM EDT - 1 year ago

Compugen to Release Second Quarter 2024 Results on Tuesday, August 6, 2024

Jun 17, 2024, 7:00 AM EDT - 1 year ago

Compugen to Present at Upcoming Antibody Industrial Symposium

May 30, 2024, 7:00 AM EDT - 1 year ago

Compugen to Receive Milestone Payment Triggered by Dosing of First Patient in the Second Phase 3 Trial Evaluating Rilvegostomig

AZN

May 20, 2024, 12:22 PM EDT - 1 year ago

Compugen Ltd. (CGEN) Q1 2024 Earnings Call Transcript

May 20, 2024, 7:00 AM EDT - 1 year ago

Compugen Reports First Quarter 2024 Results

May 16, 2024, 7:00 AM EDT - 1 year ago

Compugen Publishes Paper in Cancer Immunology Research on Unique Biology of PVRIG and its Therapeutic Potential

May 15, 2024, 7:00 AM EDT - 1 year ago

Compugen Appoints David Silberman as Chief Financial Officer

May 6, 2024, 7:00 AM EDT - 1 year ago

Compugen to Release First Quarter 2024 Results on Monday, May 20, 2024

Apr 25, 2024, 7:00 AM EDT - 1 year ago

Compugen to Present New Clinical Data Showing COM701 Triple Combination Preliminary Anti-Tumor Activity in Microsatellite Stable Colorectal Cancer with Liver Metastases at ASCO 2024

Apr 10, 2024, 7:00 AM EDT - 1 year ago

Compugen Publishes Paper in Cancer Immunology Research Demonstrating Therapeutic Potential of COM503

Apr 3, 2024, 7:00 AM EDT - 1 year ago

Compugen to Participate in Two Upcoming Investor Conferences

Mar 11, 2024, 7:00 AM EDT - 1 year ago

Compugen Selected for two Oral Presentations at the Keystone Symposium on Cancer Immunotherapy

Mar 6, 2024, 7:00 AM EST - 1 year ago

Compugen to Present Data Reflecting its Diversified Immuno-Oncology Pipeline at AACR 2024

Mar 5, 2024, 2:41 PM EST - 1 year ago

Compugen Ltd. (CGEN) Q4 2023 Earnings Call Transcript

Mar 5, 2024, 7:00 AM EST - 1 year ago

Compugen Reports Fourth Quarter and Full Year 2023 Results

Feb 26, 2024, 7:00 AM EST - 1 year ago

Compugen to Present at the Leerink Partners Global Biopharma Conference 2024

Feb 20, 2024, 7:00 AM EST - 1 year ago

Compugen to Release Fourth Quarter and Full Year 2023 Results on Tuesday, March 5, 2024

Feb 15, 2024, 7:00 AM EST - 1 year ago

Compugen Announces Appointment of Michelle Mahler M.D. as Chief Medical Officer

wenmoon_stonks Aug. 18 at 7:57 PM

$CGEN

0 · Reply

StayExcited Aug. 18 at 2:47 PM

$CGEN gotta break this 1.55! Next 1.63 Riz

0 · Reply

TwitteringTom Aug. 18 at 1:54 PM

$CGEN why this "moving" today

1 · Reply

Otus Aug. 13 at 2:43 PM

$CGEN bought a 10k block yesterday. Brings me to 240k shares. I will buy another 10k block on weakness. Long term extremely bullish!!

1 · Reply

vdonnelson Aug. 11 at 12:20 PM

$CGEN any risk of dilution to raise money in the near future, as in this month?

1 · Reply

wenmoon_stonks Aug. 7 at 2:02 PM

$CGEN shrim begin?

0 · Reply

wenmoon_stonks Aug. 6 at 2:31 PM

$CGEN

0 · Reply

Otus Aug. 6 at 2:09 PM

$CGEN wake up CGEN!! Anat exposure works better than sleeping pills

0 · Reply

TwitteringTom Aug. 5 at 6:15 PM

$CGEN what we getting tomorrow, bunch of nothing i assume

0 · Reply

Otus Jul. 28 at 9:19 PM

2 · Reply

BigSqueezeComing Jul. 21 at 11:08 AM

$CGEN pt$2.5

0 · Reply

BigSqueezeComing Jul. 21 at 11:08 AM

$CGEN Compugen Announces First Patient Dosed in COM701 Global Platform Trial in Platinum Sensitive Ovarian Cancer By PR Newswire | July 21, 2025, 7:00 AM

0 · Reply

Otus Jul. 11 at 4:11 PM

$CGEN added another 10k block today.

1 · Reply

wenmoon_stonks Jul. 8 at 3:07 AM

Reeeeeee - co - laaaaaahhhhhhh $CGEN

0 · Reply

HuntingBenjmins Jul. 5 at 3:05 AM

$CGEN One more time….lets see if they actually get some peace and we get some action on the stock price.

1 · Reply

Doozio Jul. 4 at 5:17 PM

$CGEN not that TME. But this $ZYME it’s out of the tightness 🐒🍌🧠⏰♾️

1 · Reply

RaphaelRapoport Jul. 2 at 11:57 PM

$CGEN Discovering this stock. Can someone help me shorten my DD and give me pro/con list about this company, it's potential values and time frame, etc... Thank you!

1 · Reply

wenmoon_stonks Jul. 2 at 4:16 PM

$IOVA the fact Iova and $CGEN are both trading at 1.78 RN blows my fggn mind.

1 · Reply

HuntingBenjmins Jun. 27 at 12:03 AM

$CGEN Been a long time since the last run. About ready to head back to $$3 and beyond.

2 · Reply

swingingtech Jun. 20 at 3:20 PM

$AMD $APP $CGEN $WBD https://wallstreetwaves.com/nasdaq-100-highlights-app-and-amd-surge/

0 · Reply

G101SPM Jun. 16 at 7:15 PM

#SHOWTIME ^European Association for Cancer Research Congress (June 17) Scheduled to appear: $CGEN, $PPBT ^ GE Aerospace Investor Day (June 17) Scheduled to appear: $GE ^ MercadoLibre, Inc. Annual General Meeting (June 17) Scheduled to appear: $MELI

0 · Reply

wenmoon_stonks Jun. 13 at 1:48 PM

$CGEN when will this thing get out of the penalty box?

1 · Reply

Market Cap	130.29M
Revenue (ttm)	27.86M
Net Income (ttm)	-14.23M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-51.08%
Debt to Equity Ratio	0.00

Volume	62,200
Avg Vol	204,914
Day's Range	N/A - N/A
Shares Out	89.24M
Stochastic %K	17%
Beta	2.61
Analysts	Strong Sell
Price Target	$6.25